Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Cervicovaginal safety of the formulated, biguanide-based human immunodeficiency virus type 1 (HIV-1) inhibitor NB325 in a murine model.

Lozenski K, Kish-Catalone T, Pirrone V, Rando RF, Labib M, Wigdahl B, Krebs FC.

J Biomed Biotechnol. 2011;2011:941061. doi: 10.1155/2011/941061. Epub 2011 Oct 24.

2.

A styrene-alt-maleic acid copolymer is an effective inhibitor of R5 and X4 human immunodeficiency virus type 1 infection.

Pirrone V, Passic S, Wigdahl B, Rando RF, Labib M, Krebs FC.

J Biomed Biotechnol. 2010;2010:548749. doi: 10.1155/2010/548749. Epub 2010 May 31.

3.

Specific interactions between the viral coreceptor CXCR4 and the biguanide-based compound NB325 mediate inhibition of human immunodeficiency virus type 1 infection.

Thakkar N, Pirrone V, Passic S, Zhu W, Kholodovych V, Welsh W, Rando RF, Labib ME, Wigdahl B, Krebs FC.

Antimicrob Agents Chemother. 2009 Feb;53(2):631-8. doi: 10.1128/AAC.00866-08. Epub 2008 Dec 1.

4.

Critical design features of phenyl carboxylate-containing polymer microbicides.

Rando RF, Obara S, Osterling MC, Mankowski M, Miller SR, Ferguson ML, Krebs FC, Wigdahl B, Labib M, Kokubo H.

Antimicrob Agents Chemother. 2006 Sep;50(9):3081-9.

5.

In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection.

Gu Z, Allard B, de Muys JM, Lippens J, Rando RF, Nguyen-Ba N, Ren C, McKenna P, Taylor DL, Bethell RC.

Antimicrob Agents Chemother. 2006 Feb;50(2):625-31.

6.

Polybiguanides, particularly polyethylene hexamethylene biguanide, have activity against human immunodeficiency virus type 1.

Krebs FC, Miller SR, Ferguson ML, Labib M, Rando RF, Wigdahl B.

Biomed Pharmacother. 2005 Sep;59(8):438-45.

PMID:
16154720
7.

Toward the development of a virus-cell-based assay for the discovery of novel compounds against human immunodeficiency virus type 1.

Adelson ME, Pacchia AL, Kaul M, Rando RF, Ron Y, Peltz SW, Dougherty JP.

Antimicrob Agents Chemother. 2003 Feb;47(2):501-8.

8.

Parallel synthesis of isatin-based serine protease inhibitors.

Shuttleworth SJ, Nasturica D, Gervais C, Siddiqui MA, Rando RF, Lee N.

Bioorg Med Chem Lett. 2000 Nov 20;10(22):2501-4.

PMID:
11086715
9.

Development of novel nucleoside analogues for use against drug resistant strains of HIV-1.

Rando RF, Nguyen-Ba N.

Drug Discov Today. 2000 Oct 1;5(10):465-476.

PMID:
11018598
10.

Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].

Taylor DL, Ahmed PS, Tyms AS, Wood LJ, Kelly LA, Chambers P, Clarke J, Bedard J, Bowlin TL, Rando RF.

Antivir Chem Chemother. 2000 Jul;11(4):291-301.

PMID:
10950391
11.

A novel high throughput screening assay for HCV NS3 helicase activity.

Hicham Alaoui-Ismaili M, Gervais C, Brunette S, Gouin G, Hamel M, Rando RF, Bedard J.

Antiviral Res. 2000 Jun;46(3):181-93.

PMID:
10867156
12.

Antiviral properties of a series of 1,6-naphthyridine and 7, 8-dihydroisoquinoline derivatives exhibiting potent activity against human cytomegalovirus.

Bedard J, May S, L'Heureux L, Stamminger T, Copsey A, Drach J, Huffman J, Chan L, Jin H, Rando RF.

Antimicrob Agents Chemother. 2000 Apr;44(4):929-37.

13.

Antiviral activity of 2'-deoxy-3'-oxa-4'-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice.

Stoddart CA, Moreno ME, Linquist-Stepps VD, Bare C, Bogan MR, Gobbi A, Buckheit RW Jr, Bedard J, Rando RF, McCune JM.

Antimicrob Agents Chemother. 2000 Mar;44(3):783-6.

14.

Stability-activity relationships of a family of G-tetrad forming oligonucleotides as potent HIV inhibitors. A basis for anti-HIV drug design.

Jing N, De Clercq E, Rando RF, Pallansch L, Lackman-Smith C, Lee S, Hogan ME.

J Biol Chem. 2000 Feb 4;275(5):3421-30.

15.

The hepatitis C virus NS5B RNA-dependent RNA polymerase activity and susceptibility to inhibitors is modulated by metal cations.

Alaoui-Lsmaili MH, Hamel M, L'Heureux L, Nicolas O, Bilimoria D, Labonté P, Mounir S, Rando RF.

J Hum Virol. 2000 Nov-Dec;3(6):306-16.

PMID:
11100911
16.

Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants.

Gu Z, Wainberg MA, Nguyen-Ba N, L'Heureux L, de Muys JM, Bowlin TL, Rando RF.

Antimicrob Agents Chemother. 1999 Oct;43(10):2376-82.

18.

Anti-HIV-1 activities of 1,3-dioxolane guanine and 2,6-diaminopurine dioxolane.

Gu Z, Wainberg MA, Nguyen-Ba P, L'Heureux L, de Muys JM, Rando RF.

Nucleosides Nucleotides. 1999 Apr-May;18(4-5):891-2.

PMID:
10432704
19.

Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine.

de Muys JM, Gourdeau H, Nguyen-Ba N, Taylor DL, Ahmed PS, Mansour T, Locas C, Richard N, Wainberg MA, Rando RF.

Antimicrob Agents Chemother. 1999 Aug;43(8):1835-44.

20.

Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.

Taylor DL, Ahmed PS, Chambers P, Tyms AS, Bedard J, Duchaine J, Falardeau G, Lavallée JF, Brown W, Rando RF, Bowlin T.

Antivir Chem Chemother. 1999 Mar;10(2):79-86.

PMID:
10335402
21.

A high throughput colorimetric cell proliferation assay for the identification of human cytomegalovirus inhibitors.

Bedard J, May S, Barbeau D, Yuen L, Rando RF, Bowlin TL.

Antiviral Res. 1999 Feb;41(1):35-43.

PMID:
10321577
22.
23.

Convenient approaches to the synthesis of oligonucleotide macrocycles containing non-nucleotide linkers.

Efimov VA, Buryakova AA, Kalinkina AL, Choob MV, Chakhmakhcheva OG, Ojwang JO, Rando RF.

Nucleosides Nucleotides. 1998 Jan-Mar;17(1-3):379-96.

PMID:
9708354
24.

Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir).

Esté JA, Cabrera C, Schols D, Cherepanov P, Gutierrez A, Witvrouw M, Pannecouque C, Debyser Z, Rando RF, Clotet B, Desmyter J, De Clercq E.

Mol Pharmacol. 1998 Feb;53(2):340-5.

PMID:
9463493
25.

Potassium-induced loop conformational transition of a potent anti-HIV oligonucleotide.

Jing N, Gao X, Rando RF, Hogan ME.

J Biomol Struct Dyn. 1997 Dec;15(3):573-85.

PMID:
9440003
26.

Sequence-specific inhibition of the tumor necrosis factor-alpha receptor I gene by oligodeoxynucleotides containing N7 modified 2'-deoxyguanosine.

Ojwang JO, Lewis AF, Revankar GR, Walker D, Akiyama T, Hogan ME, Rando RF.

Antisense Nucleic Acid Drug Dev. 1997 Oct;7(5):447-59.

PMID:
9361904
27.

Mode of interaction of G-quartets with the integrase of human immunodeficiency virus type 1.

Cherepanov P, Esté JA, Rando RF, Ojwang JO, Reekmans G, Steinfeld R, David G, De Clercq E, Debyser Z.

Mol Pharmacol. 1997 Nov;52(5):771-80.

PMID:
9351967
28.

Ion selective folding of loop domains in a potent anti-HIV oligonucleotide.

Jing N, Rando RF, Pommier Y, Hogan ME.

Biochemistry. 1997 Oct 14;36(41):12498-505.

PMID:
9376354
29.

Modified antisense oligonucleotides directed against tumor necrosis factor receptor type I inhibit tumor necrosis factor alpha-mediated functions.

Ojwang JO, Mustain SD, Marshall HB, Rao TS, Chaudhary N, Walker DA, Hogan ME, Akiyama T, Revankar GR, Peyman A, Uhlmann E, Rando RF.

Biochemistry. 1997 May 20;36(20):6033-45.

PMID:
9166774
30.

Effect of beta-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Implications for predicting drug hepatotoxicity.

Cui L, Schinazi RF, Gosselin G, Imbach JL, Chu CK, Rando RF, Revankar GR, Sommadossi JP.

Biochem Pharmacol. 1996 Nov 22;52(10):1577-84.

PMID:
8937473
32.

Inhibition of the human immunodeficiency virus type 1 integrase by guanosine quartet structures.

Mazumder A, Neamati N, Ojwang JO, Sunder S, Rando RF, Pommier Y.

Biochemistry. 1996 Oct 29;35(43):13762-71.

PMID:
8901518
33.

The performance of e23(Fv)PEs, recombinant toxins targeting the erbB-2 protein.

King CR, Fischer PH, Rando RF, Pastan I.

Semin Cancer Biol. 1996 Apr;7(2):79-86. Review.

PMID:
8740563
34.
35.

Intramolecular G-quartet motifs confer nuclease resistance to a potent anti-HIV oligonucleotide.

Bishop JS, Guy-Caffey JK, Ojwang JO, Smith SR, Hogan ME, Cossum PA, Rando RF, Chaudhary N.

J Biol Chem. 1996 Mar 8;271(10):5698-703.

36.

Inhibition of episomal hepatitis B virus DNA in vitro by 2,4-diamino-7- (2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-pyrrolo[2,3-d]pyrimidine.

Ojwang JO, Bhattacharya BK, Marshall HB, Korba BE, Revankar GR, Rando RF.

Antimicrob Agents Chemother. 1995 Nov;39(11):2570-3.

37.
38.

Inhibition of high affinity basic fibroblast growth factor binding by oligonucleotides.

Fennewald SM, Rando RF.

J Biol Chem. 1995 Sep 15;270(37):21718-21.

39.

Two-phase approach for the expression of high-affinity human anti-human immunodeficiency virus immunoglobulin Fab domains in Escherichia coli.

Takeda S, Dorfman NA, Robert-Guroff M, Notkins AL, Rando RF.

Hybridoma. 1995 Feb;14(1):9-18.

PMID:
7768538
40.

Suppression of human immunodeficiency virus type 1 activity in vitro by oligonucleotides which form intramolecular tetrads.

Rando RF, Ojwang J, Elbaggari A, Reyes GR, Tinder R, McGrath MS, Hogan ME.

J Biol Chem. 1995 Jan 27;270(4):1754-60.

41.

Inhibition of herpes simplex virus in culture by oligonucleotides composed entirely of deoxyguanosine and thymidine.

Fennewald SM, Mustain S, Ojwang J, Rando RF.

Antiviral Res. 1995 Jan;26(1):37-54.

PMID:
7741520
42.

Inhibition of human cytomegalovirus in culture by alkenyl guanine analogs of the thiazolo[4,5-d]pyrimidine ring system.

Lewis AF, Drach JC, Fennewald SM, Huffman JH, Ptak RG, Sommadossi JP, Revankar GR, Rando RF.

Antimicrob Agents Chemother. 1994 Dec;38(12):2889-95.

43.

Early region 3-replacement adenovirus recombinants are less pathogenic in cotton rats and mice than early region 3-deleted viruses.

Berencsi K, Uri A, Valyi-Nagy T, Valyi-Nagy I, Meignier B, Peretz FV, Rando RF, Plotkin SA, Gönczöl E.

Lab Invest. 1994 Sep;71(3):350-8.

PMID:
7933985
44.

Inhibition of Friend murine leukemia virus activity by guanosine/thymidine oligonucleotides.

Ojwang J, Okleberry KM, Marshall HB, Vu HM, Huffman JH, Rando RF.

Antiviral Res. 1994 Sep;25(1):27-41.

PMID:
7529013
45.

Inhibition of human immunodeficiency virus type 1 activity in vitro by oligonucleotides composed entirely of guanosine and thymidine.

Ojwang J, Elbaggari A, Marshall HB, Jayaraman K, McGrath MS, Rando RF.

J Acquir Immune Defic Syndr. 1994 Jun;7(6):560-70.

PMID:
7513761
46.

Inhibition of T7 and T3 RNA polymerase directed transcription elongation in vitro.

Rando RF, DePaolis L, Durland RH, Jayaraman K, Kessler DJ, Hogan ME.

Nucleic Acids Res. 1994 Feb 25;22(4):678-85.

47.

Production of human monoclonal antibodies against rabies virus.

Rando RF, Notkins AL.

Curr Top Microbiol Immunol. 1994;187:195-205. Review. No abstract available.

PMID:
7859490
48.

Murine cytotoxic T cell response specific for human cytomegalovirus glycoprotein B (gB) induced by adenovirus and vaccinia virus recombinants expressing gB.

Berencsi K, Rando RF, deTaisne C, Paoletti E, Plotkin SA, Gonczol E.

J Gen Virol. 1993 Nov;74 ( Pt 11):2507-12.

PMID:
8245869
49.

A recombinant human Fab expressed in Escherichia coli neutralizes rabies virus.

Cheung SC, Dietzschold B, Koprowski H, Notkins AL, Rando RF.

J Virol. 1992 Nov;66(11):6714-20.

50.

Detection of human serum antibodies that neutralize infectious human papillomavirus type 11 virions.

Christensen ND, Kreider JW, Shah KV, Rando RF.

J Gen Virol. 1992 May;73 ( Pt 5):1261-7.

PMID:
1316943

Supplemental Content

Loading ...
Support Center